SWOG clinical trial number
SWOG-9023

Cytogenetic and Flow Cytometric Analysis of Solid Tumors: Renal Cell Carcinoma: A Companion Study to SWOG-8949

Closed
Phase
Published
Abbreviated Title
Cytogenetic and Flow Cytometric Analysis of Solid Tumors: Renal Cell Carcinoma: A Companion Study to SWOG-8949
Activated
07/01/1993

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

2002

Cytogenetic and flow cytometric results in advanced renal cell carcinoma: a Southwest Oncology Group study

RP Whitehead;C Tangen;SR Wolman;RC Flanigan;TV Shankey;ML Slovak;ED Crawford Proc of the American Society of Clinical Oncology 21:147b(#2400)

1997

Comparison of cytogenetic and flow cytometric results of renal cell carcinoma (RCC) performed in the Southwst Oncology Group (SWOG).

SM Dobin;TS McConnell;ML Slovak;R Whitehead;V Shankey;R Flanigan Proc Seventh International Workshop on Chromosomes in Solid Tumors :#21

1993

Multidrug resistance: clinical relevance in acute leukemia

AF List Oncology 7(10):23-32

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA8185

Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase